Next Article in Journal
Integrase-Defective Lentiviral Vector Is an Efficient Vaccine Platform for Cancer Immunotherapy
Previous Article in Journal
Recent Advances in Bunyavirus Glycoprotein Research: Precursor Processing, Receptor Binding and Structure
Previous Article in Special Issue
Targeting the Complement Serine Protease MASP-2 as a Therapeutic Strategy for Coronavirus Infections
Article

Resveratrol Inhibits HCoV-229E and SARS-CoV-2 Coronavirus Replication In Vitro

1
Pathogens & Inflammation/EPILAB Laboratory, EA 4266, Université de Franche-Comté, Université Bourgogne Franche-Comté (UBFC), 25030 Besançon, France
2
Lebanese University, P.O. Box 6573/14 Badaro Museum, Beirut, Lebanon
3
FMTS, EA7292, Université de Strasbourg, IUT Louis Pasteur, 67300 Schiltigheim, France
4
Apex Biosolutions, 25000 Besançon, France
5
Department of Virology, Besancon University Hospital, 25030 Besançon, France
*
Author to whom correspondence should be addressed.
Academic Editor: Graciela Andrei
Viruses 2021, 13(2), 354; https://doi.org/10.3390/v13020354
Received: 21 January 2021 / Revised: 12 February 2021 / Accepted: 17 February 2021 / Published: 23 February 2021
(This article belongs to the Special Issue Drug-Repositioning Opportunities for Antiviral Therapy)
A novel coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), emerged in China at the end of 2019 causing a large global outbreak. As treatments are of the utmost importance, drug repurposing embodies a rich and rapid drug discovery landscape, where candidate drug compounds could be identified and optimized. To this end, we tested seven compounds for their ability to reduce replication of human coronavirus (HCoV)-229E, another member of the coronavirus family. Among these seven drugs tested, four of them, namely rapamycin, disulfiram, loperamide and valproic acid, were highly cytotoxic and did not warrant further testing. In contrast, we observed a reduction of the viral titer by 80% with resveratrol (50% effective concentration (EC50) = 4.6 µM) and lopinavir/ritonavir (EC50 = 8.8 µM) and by 60% with chloroquine (EC50 = 5 µM) with very limited cytotoxicity. Among these three drugs, resveratrol was less cytotoxic (cytotoxic concentration 50 (CC50) = 210 µM) than lopinavir/ritonavir (CC50 = 102 µM) and chloroquine (CC50 = 67 µM). Thus, among the seven drugs tested against HCoV-229E, resveratrol demonstrated the optimal antiviral response with low cytotoxicity with a selectivity index (SI) of 45.65. Similarly, among the three drugs with an anti-HCoV-229E activity, namely lopinavir/ritonavir, chloroquine and resveratrol, only the latter showed a reduction of the viral titer on SARS-CoV-2 with reduced cytotoxicity. This opens the door to further evaluation to fight Covid-19. View Full-Text
Keywords: SARS-CoV-2; HCoV-229E; resveratrol; coronavirus; viral inhibition SARS-CoV-2; HCoV-229E; resveratrol; coronavirus; viral inhibition
Show Figures

Figure 1

MDPI and ACS Style

Pasquereau, S.; Nehme, Z.; Haidar Ahmad, S.; Daouad, F.; Van Assche, J.; Wallet, C.; Schwartz, C.; Rohr, O.; Morot-Bizot, S.; Herbein, G. Resveratrol Inhibits HCoV-229E and SARS-CoV-2 Coronavirus Replication In Vitro. Viruses 2021, 13, 354. https://doi.org/10.3390/v13020354

AMA Style

Pasquereau S, Nehme Z, Haidar Ahmad S, Daouad F, Van Assche J, Wallet C, Schwartz C, Rohr O, Morot-Bizot S, Herbein G. Resveratrol Inhibits HCoV-229E and SARS-CoV-2 Coronavirus Replication In Vitro. Viruses. 2021; 13(2):354. https://doi.org/10.3390/v13020354

Chicago/Turabian Style

Pasquereau, Sébastien, Zeina Nehme, Sandy Haidar Ahmad, Fadoua Daouad, Jeanne Van Assche, Clémentine Wallet, Christian Schwartz, Olivier Rohr, Stéphanie Morot-Bizot, and Georges Herbein. 2021. "Resveratrol Inhibits HCoV-229E and SARS-CoV-2 Coronavirus Replication In Vitro" Viruses 13, no. 2: 354. https://doi.org/10.3390/v13020354

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop